Ultra-processed food linked to harm in every major human organ, study finds

A Lancet series, including a systematic review of 104 long-term studies and input from 43 experts, finds diets high in ultra-processed foods (UPF) are associated with harm to every major organ system and increased risks of obesity, type 2 diabetes, heart disease, depression and all‑cause mortality; UPF now comprises more than half of the average diet in the UK and US and can reach about 80% for some groups. The authors attribute the rapid global rise to profit-driven multinational food companies using aggressive marketing, product engineering and political lobbying to block regulation, and they call for policy actions — front-of-package labeling for UPF markers, strict marketing limits (especially to children), bans in public institutions and limits on sales and shelf space — citing Brazil’s school-food programme as a model. While critics note the UPF category and causality require more research, the papers signal clear regulatory and reputational risks for packaged-food and beverage companies and warrant investor attention to potential reformulation, labeling changes and market-share shifts across the sector.

Analysis

A Lancet series synthesizing evidence from 43 experts and a systematic review of 104 long-term studies reports that ultra-processed foods (UPF) are associated with harm to every major organ system and increased risks of obesity, type 2 diabetes, heart disease, depression and all-cause mortality; 92 of the 104 studies reviewed reported greater associated risks. The series highlights that UPF now constitutes more than half of the average diet in the UK and US and can reach roughly 80% among younger, poorer or disadvantaged groups, underscoring large population exposure.

Authors attribute the rapid global rise in UPF consumption to profit-driven corporations using product engineering, aggressive marketing and coordinated political activities to displace fresh food and resist regulation; the papers recommend front-of-package labeling for UPF markers, tighter marketing restrictions (particularly for children), bans in public institutions and limits on supermarket shelf space. The authors acknowledge methodological critiques—such as the UPF category definition and limited long-term clinical trials—but argue the existing associations merit immediate policy action.

For investors the report signals clear regulatory and reputational risk to packaged-food and beverage companies, and likely downstream impacts including reformulation costs, labeling compliance, shifts in institutional procurement (Brazil’s school program targets 90% fresh/minimally processed by 2026) and potential market-share realignments toward fresher alternatives; monitoring policy adoption and litigation or further causal research will be critical to refine exposure assessments.

Key Decisions for Investors

• Reassess exposure to packaged-food and beverage companies with a high share of UPF sales and consider reducing or hedging positions in jurisdictions where policy momentum on labeling or marketing restrictions is evident
• Actively monitor regulatory developments—front-of-package UPF markers, marketing limits for children, institutional procurement rules and supermarket shelf-space policies—as these drive near-term compliance costs and demand shifts
• Prefer or overweight companies that demonstrate credible reformulation strategies, diversified portfolios with fresh/minimally processed offerings, or successful institutional-contract pipelines (e.g., school/hospital programs)
• Engage with management on policy risk, lobbying transparency and contingency planning for reformulation and labeling costs, and consider short-duration hedges to protect against rapid regulatory or reputational shocks